# Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)

> **NCT04267120** · PHASE2 · TERMINATED · sponsor: **Washington University School of Medicine** · enrollment: 11 (actual)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** Lenvatinib
- **DRUG:** Pembrolizumab
- **PROCEDURE:** Research blood collection

## Key facts

- **NCT ID:** NCT04267120
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-07-29
- **Primary completion:** 2024-05-09
- **Final completion:** 2024-09-01
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Slow enrollment with low accrual
- **Last updated:** 2025-03-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04267120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04267120, "Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04267120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*